The survival data in the TCGA cohort showed that low SEMA3B‐AS1 expression had no effect on overall or early survival (p > 0.05, Figure S1C,D) but significantly contributed to a shorter survival time of advanced CRC patients (p = 0.044, Figure 1G). The gene discussed is SEMA3B; the disease is colorectal carcinoma.